pocketful logo light
pocketful logo light
Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

NSE: ALKEM BSE: 539523

₹5436.50

(0.61%)

Fri, 29 May 2026, 08:55 am

mtf coin illustrationMTF 5x

Alkem Laboratories Share Price Live Chart

1 Day

(0.61%)

No Result Found

Summary

  • Market Cap

    65189.83

  • Net Profit

    2216

  • P/B

    4.87

  • Sector P/E

    34.29

  • P/E

    26.94

  • EV/EBITDA

    19.35

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    19.88

  • ROCE

    20.03

  • Debt/Equity

    0.13

  • EPS (TTM)

    200.85

  • Dividend Yield

    0.83

  • Book Value

    1116.21

  • Interest Cover

    21.76

Analysis

all

thumbs up icon

Pros

  • Dividends paid are well covered by earnings (3.8x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (4.7x coverage).
  • Alkem Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Cash flow for Alkem Laboratories is expected to increase by more than 50% in 2 years time.
  • Alkem Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • Dividend payments have increased, but Alkem Laboratories only paid a dividend in the past 4 years.
  • Alkem Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Alkem Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Alkem Laboratories's earnings are expected to grow by 13.5% yearly, however this is not considered high growth (20% yearly).
  • Alkem Laboratories's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.2051.2051.2053.0455.13
FII10.169.979.489.119.41
DII21.4021.5421.9321.8019.42
Public17.2517.3017.4016.0516.05
Government00000.00

Read More

Technical Analysis

RSI

56.71

MACD

3.66

50 DMA

5417.55

200 DMA

5510.77

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic6723.336063.335731.675403.335071.674743.334083.33
Fibonacci6063.335811.215655.455403.335151.214995.454743.33
Camarilla5581.5055215460.505403.335339.5052795218.50

Pivots Level: Classic

R3

+1320

6723.33

R2

+660

6063.33

R1

+328.33

5731.67

5403.33
5403.33
Pivot Point
LTP: 5578.50

S1

-331.67

5071.67

S2

-660

4743.33

S3

-1320

4083.33

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    5470.08

  • 20-EMA

    5468.48

  • 30-EMA

    5465.43

  • 50-EMA

    5469.36

  • 100-EMA

    5484.73

  • 200-EMA

    5451.52

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
28 May 2026board-meetingsAccounts, Quarterly Results, Final Dividend
13 Feb 2026board-meetingsQuarterly Results, Interim Dividend
13 Feb 2026dividend₹43.00 Dividend /Share20 Feb 2026
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
08 Jul 2025dividendFinal Dividend - Rs. - 808 Aug 2025
29 May 2025agm
29 May 2025dividend₹8.00 Dividend /Share08 Aug 2025
07 Feb 2025dividend₹37.00 Dividend /Share14 Feb 2025
14 Jan 2025dividendInterim Dividend - Rs. - 3714 Feb 2025
10 Jul 2024dividendFinal Dividend - Rs. - 510 Aug 2024

Read More

Peer Comparison

Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Alkem Laboratories Ltd About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1973

Headquarters

CEO

Basudeo N Singh

Employees

Contact

Website icon

Website

http://www.alkemlabs.com

Email icon

Email

investors@alkem.com ; contact@alkem.com

Phone icon

Phone

91-22-39829999

Location icon

Location

Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013

Read More

Alkem Laboratories Ltd Company History

YearHistory
2019
  • Alkem crossed the revenue milestone of USD 1 billion.
  • Alkem received the Express Pharma Excellence Award at Pharma CXO Summit 2019.
  • Alkem Laboratories took over an undertaking from Cachet Pharmaceuticals.
2020
  • Alkem launched Favipiravir in India under the brand name 'Alfluenza'.
  • Alkem received the 'Best IT team of the Year' award at the CIO Conclave and Awards 2020.
2021
  • Alkem launched Ibuprofen and Famotidine Tablets in the United States.
  • Alkem launched Perampanel Tablets in India under the brand name 'Perampil'.
  • Alkem launched Brivaracetam in India under the brand name 'Brivasure'.
  • Alkem partnered with Tata Memorial Hospital.
  • Alkem was recognized as one of India's Best Workplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year.
2022
  • Alkem signed a license agreement with Harvard University's Office of Technology Development.
2023
  • The Company entered into a co-development and license agreement with Biosergen AB for the development and commercialization of BSG005.
  • The NCLT approved the Scheme of Amalgamation for the merger of Pharmasofttech Awacs Pvt. Ltd. into Pharmarack Technologies Pvt. Ltd.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTbulkSell7554004831.9211 Jun 2025
JAYANTI SINHAbulkSell17000004874.6104 Jun 2025
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTbulkSell641712468021 Feb 2025
UBS PRINCIPAL CAPITAL ASIA LIMITEDbulkSell9895065468.9925 Nov 2024
MORGAN STANLEY ASIA SINGAPORE PTE-ODIblockBuy980005732.1522 Aug 2024
COPTHALL MAURITIUS INVESTMENT LIMITED-NON ODI ACCOUNTblockBuy175005732.1522 Aug 2024
RELIANCE NIPPON LIFE INSURANCE COMPANY LIMITEDblockBuy610005732.1522 Aug 2024
CITIGROUP GLOBAL MARKETS MAURITIUS PRIVATE LTDblockBuy350005732.1522 Aug 2024
BNP PARIBAS ARBITRAGE -NON ODIblockBuy350005732.1522 Aug 2024
KOTAK MAHINDRA MUTUAL FUNDblockBuy610005732.1522 Aug 2024

Read More

Alkem Laboratories Ltd News

Alkem Labs posts Q4FY26, FY26 call audio

Alkem Laboratories Limited has released the audio recording for its Q4FY26 and FY26 earnings conference call. The recording is now accessible on the company's official investor website.

28 May 2026

companies

Alkem trading window opens June 1

Alkem Laboratories will open its trading window on June 1, 2026, following the release of Q4 and FY26 financial results.

28 May 2026

companies

Alkem re-appoints Madhurima Singh as Executive Director

Alkem Laboratories Board approved re-appointment of Mrs. Madhurima Singh as Executive Director for 5 years from Dec 20, 2026, subject to shareholder approval.

28 May 2026

companies

Alkem Labs FY26 profit rises 6% to ₹23,511.6 million

Alkem Laboratories reported a consolidated net profit of ₹23,511.6 million for FY26, a 6.1% increase. The board recommended a final dividend of ₹10 per share.

28 May 2026

companies

Alkem Labs to meet SBI Mutual Fund

Alkem Laboratories scheduled an analyst meeting with SBI Mutual Fund on May 29, 2026, in Mumbai.

25 May 2026

companies

Read More